Works by Oh, Seungjoon


Results: 35
    1
    2
    3
    4
    5
    6
    7

    Serum Adiponectin and Type 2 Diabetes: A 6-Year Follow-Up Cohort Study.

    Published in:
    Diabetes & Metabolism Journal, 2013, v. 37, n. 4, p. 252, doi. 10.4093/dmj.2013.37.4.252
    By:
    • Sun Ha Jee;
    • Chul Woo Ahn;
    • Jong Suk Park;
    • Chang Gyu Park;
    • Hyon-Suk Kim;
    • Sang-Hak Lee;
    • Sungha Park;
    • Myoungsook Lee;
    • Chang Beom Lee;
    • Hye Soon Park;
    • Heejin Kimm;
    • Sung Hee Choi;
    • Jidong Sung;
    • Seungjoon Oh;
    • Hyojee Joung;
    • Sung Rae Kim;
    • Ho-Joong Youn;
    • Sun Mi Kim;
    • Hong Soo Lee;
    • Yejin Mok
    Publication type:
    Article
    8

    Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes.

    Published in:
    Journal of Diabetes Investigation, 2013, v. 4, n. 5, p. 466, doi. 10.1111/jdi.12074
    By:
    • Son, Jang Won;
    • Kim, Dong Jun;
    • Lee, Chang Beom;
    • Oh, Seungjoon;
    • Song, Kee‐Ho;
    • Jung, Chan Hee;
    • Mok, Ji Oh;
    • Kim, Jong Hwa;
    • Moon, Min Kyong;
    • Choi, Kyung Mook;
    • Cho, Jae Hyoung;
    • Choi, Sung Hee;
    • Kim, Soo Kyung;
    • Park, Kang Seo;
    • Kim, Hye Soon;
    • Kim, In Joo;
    • Kim, Young Il;
    • Kim, Hae Jin;
    • Kim, Sang Yong;
    • Kim, Sungrae
    Publication type:
    Article
    9
    10
    11

    Tetrabromobisphenol A induces cellular damages in pancreatic β-cells in vitro.

    Published in:
    Journal of Environmental Science & Health. Part A. Toxic/Hazardous Substances & Environmental Engineering, 2017, v. 52, n. 7, p. 624, doi. 10.1080/10934529.2017.1294964
    By:
    • Suh, Kwang Sik;
    • Choi, Eun Mi;
    • Rhee, Sang Youl;
    • Oh, Seungjoon;
    • Kim, Sung Woon;
    • Pak, Youngmi Kim;
    • Choe, Wonchae;
    • Ha, Joohun;
    • Chon, Suk
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.

    Published in:
    Endocrinology & Metabolism, 2019, v. 34, n. 1, p. 53, doi. 10.3803/EnM.2019.34.1.53
    By:
    • Sang Ouk Chin;
    • Cheol Ryong Ku;
    • Byung Joon Kim;
    • Sung-Woon Kim;
    • Kyeong Hye Park;
    • Kee Ho Song;
    • Seungjoon Oh;
    • Hyun Koo Yoon;
    • Eun Jig Lee;
    • Jung Min Lee;
    • Jung Soo Lim;
    • Jung Hee Kim;
    • Kwang Joon Kim;
    • Heung Yong Jin;
    • Dae Jung Kim;
    • Kyung Ae Lee;
    • Seong-Su Moon;
    • Dong Jun Lim;
    • Dong Yeob Shin;
    • Se Hwa Kim
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27

    A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2188, doi. 10.1111/dom.15526
    By:
    • Lim, Soo;
    • Lee, Seung‐Hwan;
    • Min, Kyung‐Wan;
    • Lee, Chang Beom;
    • Kim, Sang Yong;
    • Yoo, Hye Jin;
    • Kim, Nan Hee;
    • Kim, Jae Hyeon;
    • Oh, Seungjoon;
    • Won, Jong Chul;
    • Kwon, Hyuk Sang;
    • Kim, Mi Kyung;
    • Park, Jung Hwan;
    • Jeong, In‐Kyung;
    • Kim, Sungrae
    Publication type:
    Article
    28

    Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2096, doi. 10.1111/dom.15080
    By:
    • Yang, Ye Seul;
    • Min, Kyung Wan;
    • Park, Seok‐O;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Hong, Eun‐Gyoung;
    • Cho, Sung Rae;
    • Won, Kyu Chang;
    • Kim, Yong Hyun;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Koh, Gwanpyo;
    • Huh, Wan;
    • Kim, Su Young;
    • Park, Kyong Soo
    Publication type:
    Article
    29

    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
    By:
    • Kwak, Soo Heon;
    • Han, Kyung Ah;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Kim, EunSook;
    • Won, Jong Chul;
    • Kang, Jun Goo;
    • Chung, Choon Hee;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Won, Kyu Chang;
    • Kim, Sin Gon;
    • Cho, Seung Ah;
    • Cho, Bo Young;
    • Park, Kyong Soo
    Publication type:
    Article
    30
    31
    32
    33
    34
    35